Pharmacotherapy for Autism Spectrum Disorder

Topics: Aripiprazole | Autism | Bumetanide | complementary medicine | Lurasidone | Pharmacotherapy | Risperidone | Supplements

CCPR: Welcome, Dr. Krause. Tell us a little bit about the recent paper you coauthored called Pharmacologic Management of Autism Spectrum Disorder: A Review of Seven Studies (Kothadia RJ et al, Current Psychiatry 2021;20(1):33–38). Dr. Krause: Our study was a review of reviews. The aim was to see if we could find any new insights into medication treat

Establishing a Dose-Response Relationship for Lurasidone in Acute Schizophrenia

Topics: Antipsychotics | Dose Response | Dosing | Lurasidone | Schizophrenia

REVIEW OF: Srisurapanont M et al, Sci Rep 2021:11(1):5571 STUDY TYPE: Network meta-analysis Lurasidone is FDA approved in schizophrenia, but we lack good evidence to guide its dosage. This study compared the efficacy, safety, and acceptability of lurasidone at different doses to establish a dose-response relationship for its therapeutic and adverse ef

Mood Stabilizers: What You Don’t Know Can Hurt Them

Topics: Antipsychotics | Aripiprazole | Asenapine | Bipolar Depression | Bipolar Disorder | Bipolar II | Cariprazine | Lithium | Lurasidone | Mania | Medication adherence | Mood Stabilizers | olanzapine | Oxcarbazepine | Pharmacology | Pharmacology Tips | Psychopharmacology | Psychopharmacology Tips | Quetiapine | Research | Research Update | Risperidone | safety | Saphris | Side Effects

Review of: Bai Y et al, J Clin Psychopharmacol 2020;40(2):167–179 STUDY TYPE: Combined meta-analysis and literature review of placebo-controlled trials Medication adherence is an ongoing struggle in bipolar disorder, and it’s compounded by the fact that our patients often don’t advertise their ­non-adherence. While numbers vary, reviews general